natgillin/translations-raw huggingface dataset:
The solvent composition of claim 8, wherein the solvent composition comprises between about 20.0 wt.% and about 40.0 wt.% additional solvent, optionally wherein the additional solvent comprises dipropylene glycol. 
Formulacija otapala prema patentnom zahtjevu 8, naznačen time, što formulacija otapala sadrži od oko 20,0 % masenog udjela do oko 40,0 % masenog udjela dodatnog otapala, opcionalno naznačena time što dodatno otapalo sadrži dipropilen-glikol.
Nifuratel according to claim 9, characterized in that said at least one antifungal agent is selected from: 1-hydroxy-2-pyridone compounds and their salts, e.g. ciclopirox, rilopirox, piroctone, ciclopirox olamine; imidazole derivatives and their salts, e.g. clotrimazole, econazole, isoconazole, ketoconazole, miconazole, tioconazole, bifonazole, fenticonazole and oxiconazole; polyene derivatives and their salts, e.g. nystatin, natamycin and amphotericin; allylamine derivatives and their salts, e.g. naphtifine and terbinafine; triazole derivatives and their salts, e.g. fluconazole, itraconazole, terconazole and voriconazole; morpholine derivatives and their salts, e.g. amorolfine and morpholines; griseofulvin and related compounds, e.g. griseofulvin; undecylenic acid and its salts, in particular, the zinc and calcium salts of undecylenic acid; tolnaphtate and its salts; and flucytosine and its salts. 
Nifuratel, namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što se navedeni najmanje jedan antifungik bira između: spojeva 1-hidroksi-2-piridona i njihovih soli, primjerice ciklopiroksa, rilopiroksa, piroktona, ciklopiroks olamina; derivata imidazola i njihovih soli, primjerice clotrimazola, ekonazola, izokonazola, ketokonazola, mikonazola, tiokonazola, bifonazola, fentikonazola i oksikonazola; derivata poliena i njihovih soli, primjerice nistatina, natamicina i amfotericina; derivata alilamina i njihovih soli, primjerice naftifina i terbinafina; derivata triazola i njihovih soli, primjerice flukonazola, itrakonazola, terkonazola i vorikonazola; derivata morfolina i njihovih soli, primjerice amorolfina i morfolina; grizeofulvina i srodnih spojeva, primjerice grizeofulvina; undecilenske kiseline i njenih soli, osobito cinkove i kalcijeve soli undecilenske kiseline; tolnaftata i njegovih soli; te flucitozina i njegovih soli.
The method of claim 1, wherein the at least one compound comprises a compound selected from the group consisting of: 
Spoj prema zahtjevu 1, pri čemu je spoj izabran iz grupe koja obuhvaća:
Use according to any one of claims 1 to 5, wherein the nanoparticle or nanoparticle aggregate is covered with a biocompatible coating. Use according to any one of claims 1 to 6, wherein said ionizing radiations are selected in the group consisting of X-Rays, electron beams and radioisotope emissions. 
Uporaba prema bilo kojem od zahtjeva 1 i 4, ili nanočestice HfO2 ili agregati nanočestica HfO2 za uporabu prema bilo kojem od zahtjeva 2, 3 i 4, gdje su spomenuta ionizirajuća zračenja odabrana iz skupine koju čine X-zrake, Y-zrake, elektronski snopovi i zračenja radioizotopa.
use of a compound as described in any one of clauses (1)-(160) or a pharmaceutically acceptable salt, or prodrug thereof for preparing a medicament for treating hepatitis C or a hepatitis C associated disorder in an animal; 
DOTA A (D 2 KE njegovu farmaceutski prihvatljivu sol, i (2) NS5B polimerazni inhibitor, za primjenu u kombinaciji sa NS3 proteaznim inhibitorom u profilaktičkom ili terapijskom liječenju hepatitisa C ili poremećaja povezanog sa hepatitisom €.
The compound for the use of any of claims 1 to 8, wherein at least a portion of the compound is present as a crystalline form having an X-ray diffraction pattern (CuKa) comprising significant diffraction peaks at about 8.8, 12.9, 13.4, 14.2 and 17.4°2θ. 
Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što je u najmanju ruku dio spoja prisutan kao kristalni oblik s uzorkom difrakcije rendgenskih zraka (CuKa) koji sadrži značajne difrakcijske maksimume na otprilike 8,8, 12,9, 13,4, 14,2 i 17,4° 2θ.
providing electrical stud welding or another suitable welding current source, of which a first welding current connection is electrically connected to the first metal plate and/or the second metal plate, and the equipment furthermore is provided with a welding pin or welding stud, hereinafter referred to as welding pin, to be connected with the second welding current connection, the pin having a cross section which is smaller than the cross section of the welding openings; 
osiguravanju opreme za električno zavarivanje svornjaka ili drugog pogodnog izvora struje zavarivanja, gdje se prvi kontakt za ostvarivanje struje zavarivanja (5) električno spoji s prvom metalnom pločom i/ili drugom metalnom pločom, zatim se opremi doda zatik za zavarivanje (7) ili svornjak za zavarivanje, koje se nadalje navodi kao zatik za zavarivanje, koji treba spojiti s drugim kontaktom za ostvarivanje struje zavarivanja (6), gdje zatik ima poprečni presjek manji od poprečnog presjeka otvora za zavarivanje (4);
Described herein are methods for the prevention of abnormal body weight gain or reduction of excessive body weight or obesity which comprise administering to a patient that is susceptible to abnormal body weight gain or is overweight or obese, an effective non-toxic dose of O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime or a pharmaceutically acceptable acid addition salt thereof. 
HR P20110023 T1 PATENTNI ZAHTJEVI Upotreba O-(3-piperidino-2-hidroksi-1-propil)-nikotinskog amidoksima ili njegove farmaceutski prihvatljive kisele adicijske soli naznačena time da je za pripremu farmaceutskog pripravka za prevenciju nenormalnog dobivanja na tjelesnoj težini ili za smanjenje prekomjerne težine ili pretilosti.
The holding assembly for gem positioning according to claim 4, wherein the bottom of the cavities is spaced apart from the body of the gems when these latter are positioned and held in the dial. 
Držaći sklop za smještavanje dragulja u skladu s patentnim zahtjevom 4, naznačen time što su dna šupljina (36) odmaknuta od tijela dragulja kada se potonja smjesti i drži u brojčaniku (13).
The compound of claim 1, wherein the compound is a compound according to formula I: or an enantiomer, diastereomer, tautomer, or pharmaceutically-acceptable salt or solvate thereof, wherein the symbols have the following meanings and are, for each occurrence, independently selected: 
Spoj prema zahtjevu 2, izabran iz skupine koju čine: [image] i [image] . Spoj formule III, [image] ili njegova farmaceutski prikladna sol, gdje simboli imaju sljedeća značenja i, za svako pojavljivanje, se biraju nezavisno:
A composition comprising the bacterium deposited under accession number NCIMB 42380 or a bacterium that has a 16s rRNA sequence that is at least 98% identical to SEQ ID NO:1, for use in a method of treating or preventing neutrophilic asthma. 
Sastav koji sadrži bakteriju taloženu pod pristupnim brojem NCIMB 42380 ili bakteriju koja ima 16s rRNA sekvencu koja je bar 98% identična sa SEQ ID NO:1, za upotrebu u postupku liječenja ili prevencije neutrofilne astme.
Pharmaceutical composition in the form of an aqueous suspension for oral administration comprising: 
FARMACEUTSKI PRIPRAVAK SILDENAFIL-CITRATA U OBLIKU SUSPENZIJE NAMIJENJENE ORALNOJ UPOTREBI
The sensory threshold value for this substance in water is only a few ng/kg (ppt). 
Osjetilni prag za tu tvar u vodi je samo nekoliko ng/kg (ppt).
The compound of any of claims 1-87 that is 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide. A pharmaceutical composition, comprising a compound of any one of claims 1-103 and a pharmaceutically acceptable carrier. 
Spoj formule I, naznačen time, da je to spoj 3-[5-amino-4-(3-cijanobenzoil)-pirazol-1-i1]-N-ciklopropil-4-metil-benzamid, ili njegov farmaceutski prihvatljiv derivat određen u zahtjevu 1, te da je za uporabu prema zahtjevu 1.
Hydrophobic Interaction (HI) Chromatography relies on interactions between exposed hydrophobic patches on the protein's surface and hydrophobic ligands attached to the resin. 
Kromatografija hidrofobnih interakcija ovisi o interakcijam između izloženih hidrofobnih komadića površine proteina i hidrofobnih liganada vazenih na smolu.
A process according to any of claims 1 to 4, wherein the refrigerant composition has an operating characteristic of superheat during refrigeration in the range of: 
Postupak prema bilo kojem prethodnom zahtjevu, naznačen time da rashladna tvar ima radnu karakteristiku pregrijavanja tijekom hlađenja u rasponu od:
The method of any one of clauses 31-39, wherein the influenza viruses are influenza A viruses. A method of preparing Form A of HCl salt of Compound (1)•1/2H2O, wherein Compound (1) is represented by the following structural formula: comprising: mixing HCl with Compound (1) in a solvent system comprising water and one or more organic solvents, wherein the solvent system has a water activity of 0.05-0.85. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 6-10, naznačen time što su virusi influence virusi influence tip A. Postupak priprave kristalne soli s HCI hemihidrata Spoja (1), gdje je navedena sol dodatno naznačena time što ima jedan ili više maksimuma koji odgovaraju vrijednostima 26 izmjerenim u stupnjevima od 10,5 + 0,2, 5,2 + 0,2, 7,A £ 0,2, te 18,9 + 0,2 u uzorku difrakcije rendgenskih zraka na prahu, gdje Spoj (1) prikazuje sljedeća strukturna formula: koji se sastoji u: miješanju HCI sa Spojem (1) u sustavu otapala koji sadrži vodu i jedno ili više organskih otapala, gdje sustav otapala ima aktivitet vode od 0,05-0,85.
separating precipitated aluminium phosphate from said phosphorus depleted solution, producing an aluminium depleted feed solution. 
razdvajanje (332) istaloženog aluminij fosfata iz spomenute otopine osiromašene od fosfora, kako bi se dobila otopina za raspršivanje osiromašena od aluminija.
vascular inflammations (vasculitides), 
(iv) vaskularnih upala (vaskulitisa),
reacting the resulting compound of formula V wherein R1, R2 and R3 have the meanings as described under formula I with O-methylhydroxylamine of formula VI H2N-O-CH3 (VI), to the compound of formula VII wherein R1, R2 and R3 have the meanings as described under formula I; 
-O-N=O (III), pri čemu R4 je C1-C8alkil, spoja s formulom IV [image] u inertno organsko otapalo; reakciju nastalog spoja formule V [image] pri čemu R1, R2 i R3 imaju značenja kao što je opisano pod formulom I sa O-metilhidroksilaminom s formulom VI
Typical examples of recipes for the formulation of the invention are as follows: Tablets containing 5.0 mg of a compound of the invention calculated as the free base: Compound 1 
Tipični primjeri recepata za formulaciju ovog izuma su kako slijede: 1) Tablete sadrže 5.0 mg spoja naznačenog izumom izračunatog kao slobodna baza: Spoj 1
The pharmaceutical preparation of claim 3, wherein the EDTA or derivative thereof is present in a concentration from 0.001 to 100.0 mg/ml. 
Farmaceutski pripravak prema zahtjevu 5, naznačen time da se koncentracija EDTA ili njenog derivata nalazi u rasponu od oko 0,001 do oko 100 mg/ml, ili od oko 0,1 do oko 25,0 mg/ml.
A method of treating a neurodegenerative disorder with a-synuclein pathology in an individual, or delaying onset of a neurodegenerative disorder with a-synuclein pathology in an individual at risk of developing the disorder, wherein the disorder with a-synuclein pathology is selected from the group consisting of Parkinson's disease (PD), dementia with Lewy bodies (DLB), the Lewy body variant of Alzheimer's disease, and multiple system atrophy (MSA), comprising 
Postupak proizvodnje antitijela za odgađanje početka ili za liječenje poremećaja vezanog uz a-sinuklein kod pojedinca, pri čemu je poremećaj vezan uz a-sinuklein odabran iz skupine koja se sastoji od Parkinsonove bolesti, demencije s Lewyjevim tjelešcima i/ili Lewyjevih neuritima, Alzheimerove bolesti, Downovog sindroma, multiple sistemske atrofije (MSA), drugih bolesti s patologijom Lewyjevih tjelešaca, sindroma Alzheimerove bolesti, amiotrofične lateralne skleroze, frontotemporalne demencije, Huntingtonove bolesti, prionske bolesti, Creutzfeldt Jakobove bolesti, Gerstmann-Straussler-Scheinker sindroma, kuru, fatalne familijalne nesanice, cerebrovaskularne
Y1, is an optionally substituted aryl or an optionally substituted heteroaryl; 
je opcijski supstituiran aril ili opcijski supstituiran heteroaril;
The glycosylated human SAP polypeptide of any one of claims 1-4, wherein the SAP polypeptide is a recombinant polypeptide. 
Glikozilirani humani SAP polipeptid u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time, da je SAP polipeptid rekombinantni polipeptid.
To constitute a further guiding means of the axial position of the buttress element 5 with respect to the sole 2 there is also provided, at the upper surface 10 of the area of the heel 4, seventh holes 53a or 53b provided laterally to the first seat 9 and downwardly communicating with third seats, not illustrated, adapted to house the head 54, advantageously polygonally shaped, of a fourth screw or rivet 55. 
Da bi se dobilo daljnje vodilo aksijalnog položaja potpornog elementa 5 u odnosu na potplat 2, na gornjoj površini 10 područja pete 4 su također načinjene sedme rupice 53a ili 53b, koje se nalaze bočno od prvog dosjeda 9 1 dalje niže dolaze u dodir s trećim dosjedima, što nije prikazano, prilagođenim tako da se u njih smjesti glava 54 četvrog vijka ili zakovice 55, koja ima povoljan poligonalni oblik.
Apparatus according to any of claims 2 to 4, wherein the controller controls the third heat exchanger to heat air inside the greenhouse when temperature of the inside air drops below a predetermined minimum air temperature. Apparatus according to any of the preceding claims, wherein in the maintenance mode the controller controls the fan systems of the first and second heat exchangers to draw air from outside to inside the greenhouse at an average flow rate that is substantially proportional to a volume of the greenhouse. 
Uređaj prema bilo kojem od zahtjeva 2 do 4, pri čemu kontrolor upravlja trećim izmjenjivačem topline tako da on zagrijava zrak unutar staklenika kada temperatura unutrašnjeg zraka padne ispod unaprijed određene minimalne Uređaj prema bilo kojem od prethodnih zahtjeva, pri čemu u radnom režimu održavanja kontrolor upravlja ventilatorskim sistemom prvog i drugog izmjenjivača topline tako da usisava zrak iz okoliša u unutrašnjost staklenika sa prosječnim protokom koji je u suštini proporcionalan zapremini staklenika.
The process of claim 6 wherein the suitable solvent is ethyl acetate. 
Postupak iz zahtjeva 7 gdje je prikladno otapalo etilacetat.
The integrated circuit according to claim 9 wherein the variable gap is a largest gap which is an integer multiple of the RBG size and which is available based on the applicable system bandwidth. 
Integrirani krug sukladno jednom od zahtjeva 1 do 14, naznačen time da je razmak najveći od razmaka koji su cjelobrojni višekratnici broja uzastopnih PRB-ova koji tvore RBG 1 koji su dostupni ovisno o propusnosti sustava.
In yet another embodiment of the composition described herein, the rasagiline content present in the form of rasagiline citrate is more than 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% of the total rasagiline content in the composition. 
Sastav prema jednom od patentnih zahtjeva 7-10, naznačen time, da sadržaj rasagilina u obliku rasagilin citrata iznosi više od 50% ukupnog sadržaja rasagilina u sastavu.
which process comprises converting the compound of the Formula VII to a compound of the Formula VI: 
reakciju spoja sa formulom IX sa spojem sa formulom II:
The method of claim 1 or claim 2, wherein the amino acid sequence encoded by the modified EGFR gene is at least 90% identical to SEQ ID NO: 3. 
Gen iz zahtjeva 1 ili 2, pri čemu se sekvenca aminokiselina, kodirana modificiranim EGFR genom 90% podudara sa SEQ ID NO: 3.
and subjecting the compound of formula (9) to catalytic hydrogenation to remove the protecting groups PG and, when R4′ is C2-5 alkenyl, reduce the group R4′ to C2-5 alkyl; and thereafter, where the compound of formula (6) is prepared in the form of a free base, optionally converting the free base to an acid addition salt. 
(b) podvrgavanje spoja formule (9) katalitičkoj hidrogenaciji radi uklanjanja zaštitnih skupina PG i, kada R* označava C>.s alkenil, reduciranja skupine R" na C,.s alkil; i nakon toga, gdje se spoj formule (6) pripravlja u obliku slobodne baze, izborno pretvaranja slobodne baze u kiselinsku adicijsku sol.
The dosage forms according to the invention are distinguished in that, due their hardness, they cannot be pulverised, for example by grinding in a mortar. 
Oblici davanja prema izumu odlikuju se time, da radi njihove tvrdoće nisu za pulveriziranje pomoću uobičajenih sredstava za usitnjavanje, kao mužar i tučak, a koja zlorabitelju stoje na raspolaganju.
an at least partially salified form of phosphonic acid having the general formula HxMyPO3, wherein M represents a member of the group consisting of an alkali metal, alkaline earth metal, ammonium group, or amino group, X is between 1 and 2, Y is between 1 and 2, and x +y=3, and 
Postupak prema patentnom zahtjevu 1, naznačen time što sol fosfonske kiseline ima opću formulu: H,M,PO; pri čemu: M predstavlja atom metala kao što je alkalijski ili zemno alkalijski metal, ili amonijeva skupina ili amino skupina, x jeizmeđu 112.8, yjeizmeđu0.212i
The process according to claim 1, wherein the organic material comprises a cereal grain, maize, wheat, sorghum or barley; potato; or beet molasses. 
(ili) naznačen time da organski materijal sadrži zrna žitarica, kao što su kukuruz, pšenica, sirak ili ječam; krumpir; ili melasa repe;
instructions for the use thereof; and, optionally, an adjuvant. 
C) instrukcije za uporabu istog; te, opcionalno, d) o adjuvans.
A quantity of 12 g micronized formoterol fumarate dihydrate is mixed with 100 g alpha lactose monohydrate, the mixture is given on a sieve of 0.5 mm mesh size and finally mixed again. 120 ug micronized R,R-glycopyrrolate is mixed with 1000 g alpha lactose monohydrate, the mixture is given on a sieve of 0.8 mm mesh size and finally mixed again. 
Količina od 12 g mikroniziranog formoterolfumarat dihidrata se miješa sa 100 g alfa laktoza monohidrata, smjesa se stavi na sito veličine očica od 0,5 mm i konačno opet izmiješa.120 ug mikroniziranog R,R-glikopirolata se miješa s 1000 g alfa laktoza monohidrata, smjesa se stavi na sito veličine očica od 0,8 mm i konačno opet izmiješa.
The pharmaceutical composition of claim 106 or claim 107, further comprising one or more of the following: corticosteroid, rolipram, calphostin, a CSAID, a 4-substituted imidazo[1,2-A]quinoxaline, interleukin-10, a glucocorticoid, a salicylate, nitric oxide, an immunosuppressant a nuclear translocation inhibitor, deoxyspergualin (DSG); a non-steroidal antiinflammatory drug (NSAID), ibuprofen, celecoxib, rofecoxib; a steroid, prednisone, dexamethasone; an antiviral agent, abacavir; an antiproliferative agent, methotrexate, leflunomide, FK506; a cytotoxic drug, azathioprine, cyclophosphamide, a TNF-a inhibitor, tenidap, an anti-TNF antibody, a soluble TNF receptor, and rapamycin, or derivatives thereof. 
Farmaceutski sastav prema zahtjevu 104 ili zahtjevu 105, naznačen time, da nadalje sadrži jedan ili više od sljedećih tvari: kortikosteroid, rolipram, kalfostin, CSAID, 4-supstituiran imidazo[1,2-A]kinoksalin, interleukin-10, aglukokortikoid, salicilat, dušikov oksid, imunosupresant, inhibitor nuklearne translokacije, deoksispergualin (DSG); ne-steroidni protuupalni lijek (NSAID), ibuprofen, celekoksib, rofekoksib; steroid, prednizon, deksametazon; protuvirusno sredstvo, abakavir; protuproliferativno sredstvo, metotreksat, leflunomid, FK506; citotoksični lijek, azatioprin, ciklofosfamid, inhibitor TNF-a, tenidap, ananti-TNF protutijelo, topljivi receptor TNF, irapamicin, ili njihovi derivati.
Lithium (0.65 g) was added and the reaction mixture was stirred for 10 min. 
Doda se litij (0,65 g), a reakcijsku smjesu miješa 10 minuta.
either R6 or R7 is -O-R8, -OCHR9R8, -NCH2R8 or -(CH2)2R8wherein the other R6 or R7 is hydrogen or R5; and wherein R8 is a phenyl ring or wherein the phenyl ring is optionally substituted by one or more groups independently selected from the list consisting of C1-3alkyl, halogen, cyano, haloC1-3alkyl, hydroxy, C1-3alkoxy and C1-3haloalkoxy; and is hydrogen or C1-3alkyl; which comprises: 
ili R6 ili R7 je –O-R8, -OCHR9R8, -NCH2R8 ili –(CH2)2R8 pri čemu je drugi ili R6 ili R7 vodik ili R5; i pri čemu je R8 fenilni prsten ili pri čemu je fenilni prsten opcionalno supstituiran s jednom ili više skupina neovisno izabranih s liste koja se sastoji od C1-3alkila, halogena, cijano skupine, halogen-C1-3alkila, hidroksi skupine, C1-3alkoksi skupine i C1-3halogenalkoksi skupine; i R9 je vodik ili C1-3alkil;
The FTI for use of any one of claims 1 to 7, wherein said FTI is administered at a dose of at a dose of 1-1000 mg/kg body weight. 
Spoj za uporabu u skladu s patentnim zahtjevom 1, pri čemu je tipifarnib primijenjen u dozi od 1-1000 mg/kg tjelesne mase ili pri čemu je tipifarnib primijenjen u dozi od 600 mg dva puta dnevno ili u dozi od 900 mg dva puta dnevno.
a drive shaft configured to be connected to a drive motor, 
pogonskog vratila (2) konfiguriranog da se spaja na pogonski motor, -
the nitrite is present as a nitrite solution. 
(b) je nmitrit prisutan kao otopina nitrita.
a fixing agent including gluteraldehyde present in amounts sufficient to result in concentrations at or below 0.1% under staining conditions. A method of claim 7, wherein: the particle contrast agent composition includes Crystal Violet New Methylene Blue in amounts sufficient to result in a ratio of the Crystal Violet to the New Methylene Blue between about 1:1 to about 1:500 under staining conditions; and 
Kristal violet i Novo metilensko modrilo u dovoljnoj količini da se dobiju omjer Kristal violet prema Novom metilenskom modrilu između oko 1:1 do oko 1:500 u uvjetima bojenja; i glutaraldehid u dovoljnoj količini da se dobiju koncentracije od ili ispod 0.1% u uvjetima bojenja; i inkubiranje smjese uzorka obuhvaća grijanje smjese uzorka manje od 60 sekundi.
the lower surface being shaped to correspond to one end of the hollow turning vane; 
- < donju površinu (233) takvog oblika da odgovara jednom kraju šuplje rotirajuće lopatice (201);
In a further aspect therefore, the cis-dihydrotetrabenazine may be administered prophylactically to persons of less than 30 years in age, for example in the range 10-29; more typically 15-29 or 20-29 years in age who have been tested and have been found to have mutant forms of the IT-15 gene in which the number of CAG repeats exceeds 60, and more particularly is at least 65, and preferably is 70 or more. 
Cis-dihidrotetrabenazin se može primijeniti profilaktički osobama mlađim od 30 godina, na primjer u rasponu od 10-29, češće 15-29 ili 20-29 godina starosti koje su bile testirane i kod kojih je pronađeno da imaju mutantne oblike IT- 15 gena u kojima je broj CAG ponavljanja veći od 60, povoljnije je kad je barem 65, te je još povoljnije kad je 70 ili više.
The combined ethyl acetate extract was dried (MgS04) and evaporated under vacuum to a light yellow oil slightly contaminated with diethyl succinate (477 g., 80% yield). 
Spojeni etilacetatni ekstrakt se suši (MgSOy) i ispari u vakuumu do svijetložutog ulja koje je neznatno zaprljano s dietilsukcinatnom (477 g., 80% prinos).
transition areas (554, 560) with consolidated fibrous regions that transition from the connecting regions (518) to the fiber-enriched regions (512). 
prijelazna područja (38) s konsolidiranim vlaknima koja čine prijelaz iz spojnih područja (18) u nadsvođena područja (12).
After a further 1:50 dilution in the supplemented RPMI 1640 medium, 50 uL of the diluted compounds were added to achieve a final DMSO concentration of 0.5%. 
Nakon daljnjeg 1:50 razrjeđenja u saplementiranom PRMI 1640 mediju, dodano je 50 uL od razrijeđenih spojeva da se dobije konačna koncentracija DMSO od 0.5%.
Outlet air temperature 
Temperatura izlaznog zraka